Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors	MSI-H/dMMR Solid Tumors	Recruiting	Phase 2	2026-07-10		NCT03736889

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
BeiGene	47

29 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Hebei University	Baoding	China	11
Affiliated Zhongshan Hospital of Fudan University	Shanghai	China	10
Anhui Provincial Hospital	Hefei	China	17
Beijing Cancer Hospital	Beijing	China	208
Cancer Hospital Chinese Academy of Medical Sciences	Beijing	China	71
Chongqing University Cancer Hospital	Chongqing	China	54
Fudan University Shanghai Cancer Center	Shanghai	China	27
Fujian Medical University Union Hospital	Fuzhou	China	107
Guangdong Provincial Peoples Hospital	Guangzhou	China	9
Harbin Medical University Cancer Hospital	Harbin	China	45
Henan Cancer Hospital	Zhengzhou	China	76
Hubei Cancer Hospital	Wuhan	China	95
Huizhou First Hospital	Huizhou	China	1
Hunan Cancer Hospital	Changsha	China	123
Jiangsu Province Hospital	Nanjing	China	89
Jilin Cancer Hospital	Changchun	China	9
Meizhou People Hospital	Meizhou	China	4
Nanfang Hospital of Southern Medical University	Guangzhou	China	37
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School	Nanjing	China	8
The Affiliated Hospital of Military Medical Sciences	Beijing	China	2
The first Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	China	69
The First Peoples Hospital of Yibin	Yibin	China	1
The General Hospital of Shenyang Military	Shenyang	China	1
The Peoples Hospital of Hechi	Hechi	China	1
The Sixth Affiliated Hospital, Sun Yat Sen University	Guangzhou	China	2

Clinical trials